Navigation Links
MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
Date:9/8/2010

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX™, dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

LEVADEX was well tolerated and there were no drug-related serious adverse events reported. There were no clinically significant changes in any cardiovascular parameters measured in this trial. There were no mean increases in QT interval in the LEVADEX group. All pharmacokinetic results in this trial were consistent with those reported in previous LEVADEX trials."Intravenous DHE has been used safely for over 60 years, and we wanted to evaluate whether LEVADEX, with its novel administration through the lung, would have an effect on pulmonary artery pressure. We are pleased to report that LEVADEX did not have an effect on pulmonary artery pressure compared to placebo and was, in fact, less than that seen with IV DHE," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals.

Pulmonary artery pressure in the IV DHE group was higher than both the LEVADEX and placebo groups. In addition, even after a second dose of LEVADEX was administered two hours after the first dose, pulmonary artery pressure was not higher in the LEVADEX group than in the IV DHE group.  

The PD trial was a randomized, double blind, placebo controlled, three-way, crossover trial in 24 healthy adults and was designed to compare the acute e
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
2. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
3. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
4. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
7. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
8. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
9. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 5, 2011 ORBIS and its global team of ... in Ulaanbaatar, Mongolia (June 19 - July 7) aboard ... hospital with wings. The mission was supported by Alcon ... a three-week ophthalmic skills exchange and surgical program through ...
...   The world-renowned International Journal ... addresses the thermal,aspects of radiofrequency exposure on human health. ... the controversies,surrounding huge growth and use of wireless communication. ... a quantitative,assessment of the effects of thermal energy on ...
Cached Medicine Technology:ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 2ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 3ORBIS International's Flying Eye Hospital Brings Sight Saving Skills and Technology to Ulaanbaatar, Mongolia 4Is Heat From Radiofrequency Exposure Damaging Human Health? 2Is Heat From Radiofrequency Exposure Damaging Human Health? 3
(Date:4/24/2014)... and stressful outcomes for parents who have a child ... says a recent study led by a researcher at ... numerous and life-changing and stress levels high, the vast ... reported positive outcomes as well, a phenomenon known as ... issue of the American Journal of Orthopsychiatry . ...
(Date:4/24/2014)... in the new Institute for Biomedical Sciences at ... million federal grant to develop novel therapeutics against ... from the Eunice Kennedy Shriver National Institute Of ... Institutes of Health will support Plemper,s drug development ... least one distinct alternative compound. , Infections by ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
Breaking Medicine News(10 mins):Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... Men and women of all ages are invited to enjoy this 5-day health ... ... Dr. John Spencer,Ellis invites men and women of all ages to enjoy a ... Ellis,welcomes anyone who has completed a fitness program from around the world,as well ...
... boosted pregnancy chances , , THURSDAY, Feb. 7 (HealthDay News) ... chances of becoming pregnant by up to 65 percent ... , , About 10 percent to 15 percent of ... vitro fertilization, in which a woman,s egg is fertilized ...
... ORBIS International is,saddened to announce the death ... of,directors, the Honorable Oliver Foot. He was 61 ... Oliver,s dedication to reduce human suffering caused ... a nonprofit global development,organization that transcends cultural, political ...
... with a certain gene variant drank less and ... the variant while taking the medication naltrexone, according ... Institutes of Health,s 2001-2004 COMBINE (Combined Pharmacotherapies and ... 87 percent of patients with the variant who ...
... CHASE, Md., Feb. 7 This week the,Office ... a statement that "Mr.,Heath Ledger died as the ... oxycodone, hydrocodone, diazepam, temazepam, alprazolam and,doxylamine ...We have ... accident,resulting from the abuse of prescription medications." This ...
... Finding Health and Mental Health Top the List,of Needs, ... series of tornadoes in decades, many people across the ... Cross continues to help,provide meals, shelter and clean up ... welcome help comes from Red Cross health and mental,health ...
Cached Medicine News:Health News:QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravo's The Real Housewives of Orange County 2Health News:Acupuncture May Aid In Vitro Fertilization 2Health News:Acupuncture May Aid In Vitro Fertilization 3Health News:ORBIS International Announces the Death of the Honorable Oliver Foot, President and Board Member 2Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:ASAM Calls for Care in the Use of, and the Prescribing of, Potentially Addictive Substances 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 3
... almost all its mechanical strength throughout the ... 915 months. Blunt thread design assists in ... maximize surgeons options. Driver design distributes ... help prevent the screw from breaking or ...
... FDA-cleared third-generation allergy test , 3gAllergy is ... It provides quantitative determination of allergen-specific IgE ... accuracy and lot-to-lot reproducibility. The assay delivers ... help you identify, monitor and manage patients ...
... Screw System is part of a series of ... screws ranging from 3.5 to 8.0 mm. Matching ... the system provides convenience and flexibility for the ... mm system may be customized using two of ...
The DePuy ACE 8.0mm Cannulated Cancellous Screw incorporates TiMAX to provide superior strength, fatigue resistance and a lower modulus of elasticity when compared to similar stainless steel devices....
Medicine Products: